Clinical trials for Rectal cancer

174 currently recruiting clinical trials
Phase 1 / Phase 2 Colon cancer Rectal cancer Stomach and esophageal cancer Endometrial cancer #NCT06898450
Partie C (Patients dMMR/MSI-H)
Required histologic types
Stomach
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Nimbus Wadjet, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06898450
Parties A and B (Patients non sélectionnés)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Nimbus Wadjet, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT07213817 #2025-522139-33-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Ipsen
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06923761 #2023-504845-30-00
Module 1 (Parties A, B, C, D) et module 2 (parties A et B) Tumeurs solides avancées
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Lung cancer Colon cancer Rectal cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Cervical / Vulvar / Vaginal cancer #NCT07169734 #2025-521441-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Cervical cancer
Required histologic sub types
Squamous NSCLC Adenocarcinoma Intrahepatic cholangiocarcinoma Urothelial carcinoma Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
4 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2 Lung cancer Colon cancer Rectal cancer Stomach and esophageal cancer Head and neck cancer #NCT07151040 #2024-519639-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
One-carbon Therapeutics AB
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT05118789
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Parties A1, A2, A3 (escalade de dose)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B1
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B5
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd